

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

Description

A positive airway pressure (PAP) system is a non-invasive technique for providing low levels of air pressure from a generator to a nasal or oral mask interface. It is used in the treatment of obstructive sleep apnea when the indications and limitations of the policy are met. The only diagnosis code that supports coverage of a PAP device is obstructive sleep apnea (adult or pediatric). Oral appliances for OSA (E0485 and E0486) must be processed and billed through a dentist office.

Policy

Continuous positive airway pressure devices are considered **reasonable and necessary** for members meeting coverage criteria.

Policy Guidelines

Medicare Member Coverage Criteria:

Refer to Medicare policy (L33718) and article (A52467) for coverage criteria.

Non-Medicare Member Coverage Criteria:

INITIAL COVERAGE:

A single level continuous positive airway pressure (CPAP) device (E0601) is covered for the treatment of obstructive sleep apnea (OSA) if criteria A – C are met:

- A. The member has an in-person clinical evaluation by the treating practitioner prior to the sleep test to assess the member for obstructive sleep apnea.
- B. The member has a Medicare or Health Plan-covered sleep test that meets either of the following criteria (1 or 2):
 1. The apnea-hypopnea index (AHI) or Respiratory Disturbance Index (RDI) is greater than or equal to 15 events per hour with a minimum of 30 events; or
 2. The AHI or RDI is greater than or equal to 5 and less than or equal to 14 events per hour with a minimum of 10 events and documentation of:

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

- a. Excessive daytime sleepiness, impaired cognition, mood disorders, or insomnia; or
 - b. Hypertension, ischemic heart disease, or history of stroke.
- C. The member and/or their caregiver have received instruction from the supplier of the CPAP device and accessories in the proper use and care of the equipment.

If a claim for a CPAP (E0601) is submitted and all of the criteria above have not been met, it will be denied as not reasonable and necessary.

Apnea is defined as the cessation of airflow for at least 10 seconds.

Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds associated with at least a 30% reduction in thoracoabdominal movement or airflow as compared to baseline, and with at least a 4% decrease in oxygen saturation.

The apnea-hypopnea index (AHI) is defined as the average number of episodes of apnea and hypopnea per hour of sleep without use of a positive airway pressure device. For purposes of this policy, respiratory effort related arousals (RERAs) are not included in the calculation of the AHI. Sleep time can only be measured in a Type I (facility based polysomnogram) or Type II sleep study (see descriptions below).

The respiratory disturbance index (RDI) is defined as the average number of apneas plus hypopneas per hour of recording without the use of a positive airway pressure device. For purposes of this policy, respiratory effort related arousals (RERAs) are not included in the calculation of the RDI. The RDI is reported in Type III, Type IV, and Other home sleep studies.

If the AHI or RDI is calculated based on less than 2 hours of sleep or recording time, the total number of recorded events used to calculate the AHI or RDI (respectively) must be at least the number of events that would have been required in a 2-hour period (i.e., must reach greater than or equal to 30 events without symptoms or greater than or equal to 10 events with symptoms).

PEDIATRIC MEMBERS (Ages 1 – 17):

Symptoms of sleep apnea in children may present somewhat differently than in adults, depending upon age. Common symptoms during sleep includes snoring, difficulty breathing, snorting or choking sounds, abnormal motor activity, heavy

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

sweating, arousal from sleep, nightmares and bed-wetting at an inappropriate age. Daytime symptoms caused by the disruption of normal sleep and repeated nocturnal oxygen desaturation include daytime sleepiness, irritability, hyperactivity, disciplinary problems, learning problems and headaches. In addition, chronic breathing through the mouth may indicate nasal obstruction. Many times, symptoms may be in relation to adenotonsillary hypertrophy and the symptoms are usually treated by removing the hypertrophic adenotonsillar tissue. In addition to obstructive sleep apnea, central apnea can also occur in children.

Polysomnogram results for children are considered abnormal when the apnea index (AI) is greater than one, an apnea/hypopnea index (AHI) is greater than five, blood carbon dioxide levels of 45mEq/L for more than 60 percent of sleep time or 50 mEq/L for more than 10 percent of sleep time and minimum O₂ saturation less than 92 percent.

Pediatric members (ages 1 – 17) meeting criteria of sleep apnea: (must meet at least one):

- One obstructive apnea of any length per hour
- Any central apnea of any length associated with desaturation below 90 percent
- Peak end-tidal carbon dioxide values of >53 mmHg or end-tidal carbon dioxide values of >45 mmHg for more than 60 percent of total sleep time
- SaO₂ levels of <92 percent

Central sleep apnea:

- Polysomnogram with more than five central apneas per hour of sleep lasting 10 seconds or longer
- Polysomnogram with the presence of at least 10 central events per hour of sleep in the crescendo-decrescendo pattern

Exclusions: Diagnosis of snoring without sleep apnea

Oral appliances used for the treatment of Obstructive Sleep Apnea (reference only)

Oral appliances used for the treatment of Obstructive Sleep Apnea (E0485 or E0486) require that the member has a covered sleep test that meets one of the following criteria, however, **the oral appliance must be processed and billed through a dentist's office.**

1. The apnea-hypopnea index (AHI) or Respiratory Disturbance Index (RDI) is greater than or equal to 15 events per hour with a minimum of 30 events; or,
2. The AHI or RDI is greater than or equal to 5 and less than or equal to 14 events per hour with a minimum of 10 events and documentation of:

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

- a. Excessive daytime sleepiness, impaired cognition, mood disorders, or insomnia or,
- b. Hypertension, ischemic heart disease, or history of stroke, or
3. If the AHI>30 or the RDI> 30 and meets either of the following;
 - a. The member is not able to tolerate a positive airway pressure (PAP) device or
 - b. The treating practitioner determines that the use of a PAP device is contraindicated.

Respiratory Assist Devices E0470

A RAD without backup rate (E0470) is covered for those members with OSA who meet criteria A-C above, in addition to criterion D:

- D. A single level (E0601) positive airway pressure device has been tried and proven ineffective based on a therapeutic trial conducted in either a facility or in a home setting.

Ineffective is defined as documented failure to meet therapeutic goals using an E0601 during the titration portion of a facility-based study or during home use despite optimal therapy; i.e., proper mask selection and fitting and appropriate pressure settings.

If E0470 is billed for a member with OSA and criterion A- D are not met, it will be denied as not reasonable and necessary.

A bi-level positive airway pressure device with backup rate (E0471) is not medically necessary if the primary diagnosis is OSA. If an E0471 is billed with a diagnosis of OSA, it will be denied as not reasonable and necessary:

If an E0601 device is tried and found ineffective during the initial facility-based titration or home trial, substitution of an E0470 does not require a new initial in-person clinical evaluation or a new sleep test.

If an E0601 device has been used for more than 3 months and is subsequently substituted with an E0470 (RAD), a new initial in-person clinical evaluation is required, but a new sleep test is not required. A new 3-month trial would begin for use of the E0470.

Coverage, coding and documentation requirements for the use of RAD's for diagnoses other than OSA are addressed in the RAD policy.

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

Coverage of a PAP device for the treatment of OSA is limited to claims where the diagnosis of OSA is based upon a sleep test. (Type I, II, III, or IV). The sleep test must be either a polysomnogram performed in a facility-based laboratory (Type I study) or a home sleep test (HST) Types II, III, or IV, Other). The test must be ordered by the member's treating practitioner and conducted by an entity that qualifies as a Medicare or Health Plan provider of sleep tests and is in compliance with all applicable state regulatory requirements.

Sleep Tests:

A **Type I sleep test** is the continuous and simultaneous monitoring and recording of various physiological and pathophysiological parameters of sleep with practitioner's review, interpretation, and report. It is facility –based and must include sleep staging, which is defined to include a 1-4 lead electroencephalogram (EEG), electro-oculogram (EOG), submental electromyogram (EMG) and electrocardiogram (ECG). It must also include at least the following additional parameters of sleep: airflow, respiratory effort, and oxygen saturation by oximetry. It may be performed as either a whole night study for diagnosis only or as a split night study to diagnose and initially evaluate treatment.

A HST is performed unattended in the member's home using a portable monitoring device. A portable monitoring device for conducting an HST must meet one of the following criteria:

- A. **Type II device** - Monitors and records a minimum of seven (7) channels: EEG, EOG, EMG ECG/heart rate, airflow, respiratory movement/effort and oxygen saturation; or,
- B. **Type III device** - Monitors and records a minimum of four (4) channels: respiratory movement/effort, airflow, ECG/heart rate and oxygen saturation; or,
- C. **Type IV device** – Monitors and records a minimum of three (3) channels, one of which is airflow; or
- D. **Other** - Devices that monitor and record a minimum of three (3) channels that include actigraphy, oximetry, and peripheral arterial tone and for which there is substantive clinical evidence in the published peer-reviewed literature that demonstrates that the results accurately and reliably correspond to an AHI or RDI as defined above. This determination will be made on a device by device basis.

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

For PAP devices with initial dates of service on or after Nov.1, 2008, all members who undergo a HST must, prior to having the test, receive instruction on how to properly apply a portable sleep monitoring device. This instruction must be provided by the entity conducting the HST and may not be performed by a DME supplier. Member instruction may be accomplished by either:

1. Face-to-face demonstration of the portable sleep monitoring device's application and use; or,
2. Video or telephonic instruction, with 24-hour availability of qualified personnel to answer questions or troubleshoot issues with the device.

For PAP devices with initial dates of service on or after Nov.1, 2008, all HST's (Type II, III, or IV, or Other) must be interpreted by a practitioner who holds either:

1. Current certification in Sleep Medicine by the American Board of Sleep Medicine (ABSM); or
2. Current subspecialty in Sleep Medicine by a member board of the American Board of Medical Specialties; or
3. Completed residency or fellowship training by an ABMS member board and has completed all the requirements for subspecialty certification in sleep medicine except the examination itself and only until the time of reporting of the first examination for which the practitioner is eligible; or
4. Active staff membership of a sleep center or laboratory accredited by the American Academy of Sleep Medicine (AASM) or the Joint Commission.

For PAP devices with coverage based on a facility-based polysomnogram (Type I) performed on or after January 1, 2010, the interpreting practitioner must meet one of the requirements listed above (1-4) for credentialing.

ACCESSORIES:

1. Accessories used with a PAP device are covered when the coverage criteria for the device are met. If the coverage criteria are not met, the accessories will be denied as not reasonable and necessary.

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

- Quantities of supplies greater than those described in the policy as the usual maximum amounts, in the absence of documentation clearly explaining the medical necessity of the excess quantities, will be denied as not reasonable and necessary.

The following table represents the usual maximum amount of accessories expected to be medically necessary:

Procedure Code	Usual Maximum Amount
A4604	1 per 3 months
A7027	1 per 3 months
A7028	2 per 1 month
A7029	2 per 1 month
A7030	1 per 3 months
A7031	1 per 1 month
A7032	2 per 1 month
A7033	2 per 1 month
A7034	1 per 3 months
A7035	1 per 6 months
A7036	1 per 6 months
A7037	1 per 3 months
A7038	2 per 1 month
A7039	1 per 6 months
A7046	1 per 6 months

- A PAP (E0601) device should include as standard equipment, integrated heat and humidification.
- For PAP (E0470, E0471, E0472) either a non-heated (E0561) or heated (E0562) humidifier is reasonable and necessary when ordered by the treating practitioner for use with a covered PAP (E0470, E0471, E0472).

REPLACEMENT:

If a PAP device is replaced during the 5-year reasonable useful lifetime because of loss, theft, or irreparable damage due to a specific incident, there is no requirement for a new clinical evaluation, sleep test, or trial period.

If a PAP device is replaced following the 5-year reasonable useful lifetime, there must be a in-person evaluation by their treating practitioner that documents that the member

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

continues to use and benefit from the PAP device. There is no requirement for a new sleep test or trial period.

CONTINUED COVERAGE BEYOND THE FIRST THREE MONTHS OF THERAPY

Continued coverage of a PAP device (E0470 or E0601) beyond the first three months of therapy requires that, no sooner than the 31st day but no later than the 91st day after initiating therapy, the treating practitioner must conduct a clinical re-evaluation and document that the member is benefiting from PAP therapy (note: see Special Coverage Information section for HNE).

For PAP devices with initial dates of service on or after November 1, 2008, documentation of clinical benefit is demonstrated by:

1. In-person clinical re-evaluation by the treating practitioner with documentation that symptoms of obstructive sleep apnea are improved; and,
2. Objective evidence of adherence to use of the PAP device, reviewed by the treating practitioner.

Adherence to therapy is defined as use of PAP ≥ 4 hours per night on 70% of nights during a consecutive thirty (30) day period anytime during the first three (3) months of initial usage.

If the above criteria are not met, continued coverage of a PAP device and related accessories will be denied as not reasonable and necessary.

If the treating practitioner re-evaluation does not occur until after the 91st day but the evaluation demonstrates that the member is benefiting from PAP therapy as defined in criteria 1 and 2 above, continued coverage of the PAP device will commence with the date of that re-evaluation.

Members who fail the initial 12-week trial are eligible to re-qualify for a PAP device but must have both:

1. In-person clinical re-evaluation by the treating practitioner to determine the etiology of the failure to respond to PAP therapy; and,

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

2. Repeat sleep test in a facility-based setting (Type 1 study). This may be a repeat diagnostic, titration or split-night study.

If an E0601 device is tried and found ineffective during the initial facility-based titration or home trial, substitution of an E0470 does not change the length of the trial unless there is less than 30 days remaining in the trial period. If more than 30 days remain in the trial period, the clinical re-evaluation would still occur between the 31st and 91st day following the initiation of an E0601 and objective documentation of adherence on the E0470 would need to occur prior to the 91st day following initiation of the E0601. If less than 30 days remain in the trial period, the clinical re-evaluation and objective documentation of adherence must occur before the 120th day following the initiation of the E0601.

If an E0601 device was used for more than 3 months and the member was then switched to an E0470, the clinical re-evaluation must occur between the 31st and 91st day following the initiation of the E0470. There would also need to be documentation of adherence to therapy during the 3-month trial with the E0470. If there is discontinuation of usage of a PAP device at any time, the supplier is expected to ascertain this and stop billing for the equipment and related accessories and supplies.

For a PAP device dispensed prior to November 1, 2008, if the initial Medicare coverage criteria in effect at the time were met and the criteria for coverage after the first 3 months that were in effect at the time were met, the device will continue to be covered for dates of service on or after November 1, 2008 as long as the member continues to use the device.

ICD-10 Codes That Support Medical Necessity:

ICD-10 CODE	DESCRIPTION
G47.33	Obstructive sleep apnea (adult) (pediatric)

ICD-10 Codes That Do Not Support Medical Necessity:

All ICD-10 codes that are not specified in the preceding section.

EXCLUSIONS:

- A liner used in conjunction with a PAP mask is considered comfort/convenience item. There is no additional payment for liners used with a PAP mask. These products should be coded A9270 (Noncovered item or service).

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

- Claims for A9279 (MONITORING FEATURE/DEVICE, STAND-ALONE OR INTEGRATED, ANY TYPE, INCLUDES ALL ACCESSORIES, COMPONENTS AND ELECTRONICS, NOT OTHERWISE CLASSIFIED) are denied as statutorily non-covered (No Medicare benefit).
- Code A9279 describes any type of monitoring technology. Code A9279 is all-inclusive and is to be used whether the monitoring technology is incorporated as part of a base item, supplied as an add-on module or is a stand-alone item.
- Electronic Positional Devices for the Treatment of Obstructive Sleep Apnea (**E0530**) are **considered investigational and not medically necessary** in the treatment of obstructive sleep apnea.

This device is designed to be used in the treatment of positional obstructive sleep apnea (POSA). Positional therapy prevents individuals from sleeping in the supine position and can decrease or eliminate obstructive events in POSA. A new generation of electronic positional therapy devices have been suggested as an alternative to the current treatments. Several devices are currently available on the market, including the NightBalance Lunoa system (Philips; Cambridge, MA) or Night Shift (Advanced Brain Monitoring, Carlsbad, CA).

(The following code E0467 is not appropriate for the treatment of OSA – refer to Ventilators Policy).

Code E0467 (HOME VENTILATOR, MULTI-FUNCTION RESPIRATORY DEVICE, ALSO PERFORMS ANY OR ALL OF THE ADDITIONAL FUNCTIONS OF OXYGEN CONCENTRATION, DRUG NEBULIZATION, ASPIRATION, AND COUGH STIMULATION, INCLUDES ALL ACCESSORIES, COMPONENTS AND SUPPLIES FOR ALL FUNCTIONS) describes a ventilator that integrates the function of multiple types of equipment into a single device. Code E0467 combines the function of a ventilator with those of any combination of or all of the following:

- Oxygen equipment
- Nebulizer and compressor

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

- Aspirator (suction device)
- Cough stimulator (multiple products)
- Positive airway pressure devices (PAP and RAD)
- Custom fabricated oral appliances

The following positive airway pressure devices HCPCS codes for individual items are included in the functionality of code E0467:

- HCPCS codes E0470, E0471, E0472, E0601, A4604, A7027, A7028, A7029, A7030, A7031, A7032, A7033, A7034, A7035, A7036, A7037, A7038, A7039, A7044, A7045, A7046, E0561, E0562

Claims for any of the HCPCS codes listed above that are submitted on the same claim or that overlap any date(s) of service for E0467 is considered to be unbundling.

In addition, any claim for repair (HCPCS code K0739 for labor and any HCPCS code for replacement items) of member-owned equipment identified by HCPCS codes listed above is considered as unbundling if the date(s) of service for the repair overlaps any date(s) of service for code E0467.

Claims for code E0467 with a date(s) of service that overlaps date(s) of service for any of the following scenarios are considered as a claim for same or similar equipment when the member:

- Is currently in a rental month for any of the items listed above
- Owns any of the equipment listed above that has not reached the end of its reasonable useful lifetime

HCPCS Level II Codes and Description

Equipment:

E0470 RESPIRATORY ASSIST DEVICE, BI-LEVEL PRESSURE CAPABILITY, WITHOUT BACKUP RATE FEATURE, USED WITH NONINVASIVE INTERFACE, E.G. NASAL OR FACIAL MASK (INTERMITTENT ASSIST DEVICE WITH CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICE)

E0471 RESPIRATORY ASSIST DEVICE, BI-LEVEL PRESSURE CAPABILITY, WITH BACK-UP RATE FEATURE, USED WITH NONINVASIVE INTERFACE, E.G., NASAL OR FACIAL MASK (INTERMITTENT ASSIST DEVICE WITH CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICE).

E0472 RESPIRATORY ASSIST DEVICE, BI-LEVEL PRESSURE CAPABILITY,

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

WITH BACKUP RATE FEATURE, USED WITH INVASIVE INTERFACE, E.G. TRACHEOSTOMY TUBE (INTERMITTENT ASSIST DEVICE WITH CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICE)

E0601 CONTINUOUS AIRWAY PRESSURE (CPAP) DEVICE

Accessories:

A4604 TUBING WITH INTEGRATED HEATING ELEMENT FOR USE WITH POSITIVE AIRWAY PRESSURE DEVICE

A7030 FULL FACE MASK USED WITH POSITIVE AIRWAY PRESSURE DEVICE, EACH

A7031 FACE MASK INTERFACE, REPLACEMENT FOR FULL FACE MASK, EACH

A7032 CUSHION FOR USE ON NASAL MASK INTERFACE, REPLACEMENT ONLY, EACH

A7033 PILLOW FOR USE ON NASAL CANNULA TYPE INTERFACE, REPLACEMENT ONLY, PAIR

A7034 NASAL INTERFACE (MASK OR CANNULA TYPE) USED WITH POSITIVE AIRWAY PRESSURE DEVICE, WITH OR WITHOUT HEAD STRAP

A7035 HEADGEAR USED WITH POSITIVE AIRWAY PRESSURE DEVICE

A7036 CHINSTRAP USED WITH POSITIVE AIRWAY PRESSURE DEVICE

A7037 TUBING USED WITH POSITIVE AIRWAY PRESSURE DEVICE

A7038 FILTER, DISPOSABLE, USED WITH POSITIVE AIRWAY PRESSURE DEVICE

A7039 FILTER, NON-DISPOSABLE, USED WITH POSITIVE AIRWAY PRESSURE DEVICE

A7044 ORAL INTERFACE USED WITH POSITIVE AIRWAY PRESSURE DEVICE, EACH

A7045 EXHALATION PORT WITH OR WITHOUT SWIVEL USED WITH ACCESSORIES, REPLACEMENT ONLY

A7046 WATER CHAMBER FOR HUMIDIFIER, USED WITH POSITIVE AIRWAY PRESSURE DEVICE, REPLACEMENT, EACH

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

A7049 EXPIRATORY POSITIVE AIRWAY PRESSURE INTRANASAL RESISTANCE VALVE

E0561 HUMIDIFIER, NON-HEATED, USED WITH POSITIVE AIRWAY PRESSURE DEVICE

E0562 HUMIDIFIER, HEATED, USED WITH POSITIVE AIRWAY PRESSURE DEVICE

HCPCS CODES NOT COVERED:

E0530 Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type (Investigational)

Documentation Requirements

1. Initial coverage - A copy of the initial sleep study and the PAP titration study must be submitted with the initial claim. **The date of the sleep study must be less than a year old when initiating new therapy.** (Per Medicare guidelines - Timely documentation is defined as a record in the preceding 12 months unless otherwise specified elsewhere in the policy).
2. Items in this policy may be subject to the Affordable Care Act (ACA) 6407 requirements. The Affordable Care Act (ACA) 6407 requires that the treating physician conduct a face-to-face examination during the six-month period preceding the written order. The documentation must be received by the provider prior to delivery for certain DME items. The documentation must describe a medical condition for which the DME is being prescribed.

Important Note:

Northwood's Medical Policies are developed to assist Northwood in administering plan benefits and determining whether a particular DMEPOS product or service is reasonable and necessary. Equipment that is used primarily and customarily for a non-medical purpose is not considered durable medical equipment.

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

Coverage determinations are made on a case-by-case basis and are subject to all of the terms, conditions, limitations, and exclusions of the member's contract including medical necessity requirements.

The conclusion that a DMEPOS product or service is reasonable and necessary does not constitute coverage. The member's contract defines which DMEPOS product or service is covered, excluded or limited. The policies provide for clearly written, reasonable and current criteria that have been approved by Northwood's Medical Director.

The clinical criteria and medical policies provide guidelines for determining the medical necessity for specific DMEPOS products or services. In all cases, final benefit determinations are based on the applicable contract language. To the extent there are any conflicts between medical policy guidelines and applicable contract language, the contract language prevails. Medical policy is not intended to override the policy that defines the member's benefits, nor is it intended to dictate to providers how to direct care. Northwood Medical policies shall not be interpreted to limit the benefits afforded to Medicare or Medicaid members by law and regulation and Northwood will use the applicable state requirements to determine required quantity limit guidelines.

Northwood's policies do not constitute medical advice. Northwood does not provide or recommend treatment to members. Members should consult with their treating practitioner in connection with diagnosis and treatment decisions.

Northwood follows all CMS National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), as applicable.

Cross Reference to Related Policies and Procedures

Centers for Medicare and Medicaid Services, Medicare Coverage Database, National Coverage Documents; November 2011.

CGS Administrators, LLC. Jurisdiction B DME MAC, Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea. Local Coverage Determination No. L33718; Last accessed/Reviewed December 24, 2025.

Noridian Healthcare Solutions, LLC. Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea. Local Coverage Determination No. L33718. Durable Medical Equipment Medicare Administrative Carrier Jurisdiction A; Last accessed/reviewed December 24, 2025.

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

Aetna Obstructive Sleep Apnea in Adults Clinical Policy Bulletin Number 0004
https://www.aetna.com/cpb/medical/data/1_99/0004.html Last accessed and reviewed 5/12/2026.

Anthem: Coverage and clinical guideline update; Anthem DME.00042
https://www.anthem.com/dam/medpolicies/abcbs/active/policies/mp_pw_e000515.html
 Last accessed and reviewed 12/11/25.

Blue Cross Blue Shield of Florida 09-E0000-21 Subject: Positive Airway Pressure Devices
 Last accessed and reviewed 12/11/25.

SPECIAL COVERAGE INFORMATION PER PLAN:

HEALTH NEW ENGLAND	<p>Continued coverage of a CPAP and its supplies does NOT require a face-to-face (F2F) physician visit for its Commercial or Medicare members. F2F only required for initial coverage.</p> <p>Required: Nurse documentation stating member is benefiting from CPAP usage as well as any issues member is having with CPAP and/or supplies (if applicable).</p>
---------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Change/Authorization History

Revision Number	Date	Description of Change	Prepared / Reviewed by	Approved by	Review Date:	Effective Date:
A	11-20-06	Initial Release	Rosanne Brugnani	Ken Fasse	n/a	
01	08-2007	Deleted HCPC codes K0553-K0555	Rosanne Brugnani	Ken Fasse	n/a	

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

02	03/2008	<p>Added: definition of Type IV device. Extended implementation dates for credentialing of physicians interpreting home sleep tests and facility-based polysomnograms. Requirement for beneficiary education by entity conducting home sleep test. Expanded dates during which members must be re-evaluated for documenting benefit from PAP therapy. Expanded dates for members switched from CPAP to RAD with less than 30 days remaining in initial trial period. Added: Requalifying after failed initial 12-week trial of PAP therapy. Documentation: Expanded dates for documentation of benefit from PAP therapy. Documentation of adherence to PAP therapy to allow visual inspection of usage data. Changed title from Continuous Positive Airway Pressure System (CPAP) to Positive Airway Pressure (PAP) Devices for the treatment of OSA to reflect addition of coverage for RAD's. Revised coverage criteria for CPAP to include home sleep testing and face-to-face clinical evaluation and re-evaluation. Use of RAD's for OSA from the Respiratory Assist Devices to this policy. Coverage criteria for changing from a CPAP to RAD's both before and after the first 3 months of PAP therapy. Added criteria for portable sleep monitoring devices. Added requirements for administering and interpreting home sleep studies Added Information about documenting adherence and clinical re-evaluation Epworth Sleepiness Scale can be found in the Master P&P manual in the LCD.</p>	Susan Glomb	Ken Fasse		
03	12-2008	Annual Review. No additional changes	Susan Glomb	Ken Fasse		

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

04	01-2009	Revised criteria for Type IV home sleep test device. Added resource to identify list of approved Type IV devices that do not report AHI/RDI based on direct measurement of airflow or thoracoabdominal movement. (WatchPAT-100)	Susan Glomb	Ken Fasse		
05	09-01-09	Added GA and GZ modifiers. Revised KX modifier Added information about the required use of KX, GA or GZ on claim lines for PAP devices and/or accessories.	Susan Glomb	Ken Fasse		
06	12-4-09	Annual Review. No changes.	Susan Glomb	Ken Fasse	Dec. 2009	
07	12-03-10	Annual Review – No changes	Susan Glomb	Ken Fasse	Dec. 2010	
08	01-07-11	Delete least costly alternative language for Codes E0470 and E0471. Revised requirements for documenting ineffective therapy on E0601. Added: Program integrity manual instructions on refills of accessories. Revised types of sleep tests. Coverage of replacement devices and/or accessories.	Susan Glomb	Ken Fasse	Jan 2011	
09	04-19-11	Policy updated to reflect current changes.	Susan Glomb	Dr. B. Almasri		
09	07-05-11	Policy updated to reflect current changes.	Susan Glomb	Dr. B. Almasri		
10	07-20-11	Added Important Note to all Medical Policies	Susan Glomb	Dr. B. Almasri		
11	11-28-11	Annual Review. Added References to Policy	Susan Glomb	Dr. B. Almasri	Nov. 2011	
12	04-04-12	Added reference to NH Medicaid	Susan Glomb	Dr. B. Almasri		
13	12-4-12	Annual Review – No changes	Susan Glomb	Dr. B. Almasri	Dec 12	

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

14	12-18-13	Annual review with changes pending. Added further description to policy stating that the only diagnosis for coverage is OSA.	Susan Glomb	Dr. B. Almasri	Dec 2013	
15	12-4-2014	Annual Review. Added: Items in this policy may be subject to the Affordable Care Act (ACA) 6407 requirements.	Susan Glomb	Dr. B. Almasri		
16	12-16-15	Annual Review. Added noncovered information regarding liners used with a PAP mask.	Lisa Wojno	Dr. B. Almasri		
17	12-08-16	Annual Review. No Changes.	Lisa Wojno	Dr. B. Almasri	December 2016	
18	12-19-17	Annual review. No changes.	Carol Dimech	Dr. C. Lerchin	December 2017	
19	9-7-18	Added information regarding A9279 monitoring device.	Carol Dimech	Dr. C. Lerchin	September 2018	
20	12-13-18	Annual review. See changes 9/7/18. Medicare references updated.	Carol Dimech	Dr. C. Lerchin	December 2018	
21	12-20-19	Annual review. Added ICD-10 covered and noncovered codes; documentation requirements; E0467 coding guidelines.	Carol Dimech	Dr. C. Lerchin	December 2019	12-20-19
22	12-11-20	Annual review. Per CMS, revised “ordering physician” to “treating practitioner”; revised “(Non) Covered Codes” verbiage to “Supports (Does not Support) Medical Necessity”; “Face-to-Face” to “In-Person”.	Carol Dimech	Dr. C. Lerchin	December 11, 2020	12-11-20
23	12-14-21	Annual Review. Added NCD/ LCD verbiage to “Important Note”.	Carol Dimech/Susan Glomb	Dr. C. Lerchin	December 14, 2021	
24	9-8-22	Added HCPCS code K1001 and description to non-covered list. Added references.	Carol Dimech	Dr. C. Lerchin	9-8-22	9-8-2022
25	12-15-22	Annual review. No additional changes since last entry on 9/8/22.	Carol Dimech	Dr. C. Lerchin	12-15-22	12-15-22
26	12-11-23	Annual review. No changes.	Carol Dimech	Dr. C. Lerchin	12-11-23	12-11-23

Medical Policy



Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea

27	12-5-24	Annual review. HCPCS coding update: Code E0530 added; code K1001 deleted.	Carol Dimech	Dr. C. Lerchin	12-5-24	12-5-24
28	12-11-25	Annual review. No changes.	Susan Kazmierski	Dr. C. Lerchin	12-11-25	12-11-25
29	12-24-25	Added: "Continued Coverage Beyond the First Three Months of Therapy" criteria.	Susan Kazmierski	Dr. C. Lerchin	12-24-25	12-24-25
30	01-13-26	Added Special Coverage Information for HNE to not require F2F for continued coverage of PAP.	Susan Kazmierski	Dr. C. Lerchin	01-13-26	03-01-26
31	5-12-2026	Added A7049.	Susan Kazmierski	Dr. C. Lerchin	5-12-2026	5-12-2026